-
Published: July, 2024Source: 2024 JAMA Oncology
B-Cell Maturation Antigen/CD19 Dual-Targeting Immunotherapy in Newly Diagnosed Multiple Myeloma
B-Cell Maturation Antigen/CD19 Dual-Targeting Immunotherapy in Newly Diagnosed Multiple Myeloma
-
Published: June, 2024Source: 2024 EHA Annual Meeting
A phase I open-label single-arm study of dual targeting BCMA and CD19 FasTCAR-T AZD0120 (GC012F) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma
A phase I open-label single-arm study of dual targeting BCMA and CD19 FasTCAR-T AZD0120 (GC012F) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma
-
Published: November, 2023Source: 2023 ASH Annual Meeting
Updated Results of a Phase I Open-Label Single-Arm Study of Dual Targeting BCMA and CD19 Fastcar-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma
Updated Results of a Phase I Open-Label Single-Arm Study of Dual Targeting BCMA and CD19 Fastcar-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma
-
Published: November, 2023Source: 2023 SITC Annual Meeting
SMART CAR-T cells resist tumor immunosuppressive microenvironment with enhanced efficacy against solid tumors
Poster - SMART CAR-T cells resist tumor immunosuppressive microenvironment with enhanceo efficacy against solid tumors
-
Published: September, 2023Source: 2023 IMS Annual Meeting
Phase I open-label single-arm study of dual targeting BCMA and CD19 FasTCAR-T cells (GC012F) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma
Phase I open-label single-arm study of dual targeting BCMA and CD19 FasTCAR-T cells (GC012F) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma
-
Published: May, 2023Source: 2023 ASCO Annual Meeting, 2023 EHA Congress
Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM)
Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM)
-
Published: May, 2023Source: 2023 ASCO Annual Meeting, 2023 EHA Congress
Updated clinical results of first-in-human study of CD19/BCMA dual-targeting fast CAR-T GC012F for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma
ASCO 2023 Poster - Updated Clinical Results of First-in-Human Study of CD19/BCMA Dual-Targeting FasT CAR-T GC012F for Patients with Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma
-
Published: May, 2023Source: 2023 EHA Congress
Donor-derived Anti-CD19 Chimeric Antigen Receptor T Cells for B-cell Acute Lymphoblastic Leukemia: a Phase 1 Trial
-
Published: November, 2022Source: 2022 ASH Annual Meeting Abstract
Phase I Open-Label Single-Arm Study of BCMA/CD19 Dual-Targeting FasTCAR-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma
Data Presentation - Phase I Open-Label Single-Arm Study of BCMA/CD19 Dual-Targeting FastCAR-T GC012F as First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma
-
Published: June, 2022Source: 2022 EHA Annual Congress Abstract
Updated results of a multicenter first-in-human study of BCMA/CD19 dual-targeting FasTCAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM)
EHA 2022 - Oral Presentation – Updated results of a multicenter first-in-human study of BCMA/CD19 dual-targeting FasTCAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM)